A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis

Trial Profile

A Phase IIa, Single Blind, Randomized, Study to Evaluate the Safety, the Immunogenicity, and the Clinical and Biological Efficacy of IFNα-Kinoid (IFN-K) in Adult Subjects With Dermatomyositis

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Sep 2017

At a glance

  • Drugs Interferon alpha kinoid (Primary)
  • Indications Dermatomyositis
  • Focus Pharmacodynamics; Proof of concept
  • Sponsors Neovacs
  • Most Recent Events

    • 19 Jul 2017 According to a Neovacs media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for IFNalpha Kinoid in the treatment of dermatomyositis, which allows the Company to initiate this Phase IIa clinical trial in the US.
    • 04 May 2017 According to a Neovacs media release, results of this study, will provide data to support the design and execution of a pivotal study.
    • 30 Mar 2017 According to a Neovacs media release, preliminary results from this trial are expected in the second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top